News

Work on Pulmatrix’s PUR1900 for Fungal Infections in CF Patients Bolstered by FDA

The U.S. Food and Drug Administration (FDA) has designated PUR1900 a Qualified Infectious Disease Product (QIDP) as a potential treatment of fungal infections in the lungs of patients with cystic fibrosis(CF), its developer, Pulmatrix, announced. This  designation accelerates the development of new treatments against infectious agents, and protects the exclusivity of PUR1900 for…

Patients, Parents Fearful of Initial Bacterial Lung Infection, Survey Finds

The emotional impact of an initial Pseudomonas aeruginosa (PA) respiratory infection on cystic fibrosis (CF) patients and those close to them is considerable, and it can lead them to adopt preventive measures that may be ineffectual and intrusive, researchers have found. For the study, “Perception of first respiratory infection…

First Allied Securities Donates $73,000 to Cystic Fibrosis Foundation

First Allied Securities has given the Cystic Fibrosis Foundation a $73,487 donation for research and programs dealing with the disease. Archie Manning, a retired National Football League quarterback, donated memorabilia that First Allied’s charity arm, First Philanthropy, auctioned for some of the donation. In the past seven years, First Philanthropy has…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.